Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Fort Worth, Texas 76134


Purpose:

Assess safety and efficacy of transitioning uncontrolled glaucoma patients currently on Xalatan to adding either Azopt or Placebo TID.


Criteria:

Inclusion Criteria: - Unilateral or bilateral primary open angle glaucoma, ocular hypertension or pseudoexfoliation syndrome - IOP > 18mm Hg (mean diurnal) and less than 32 mm Hg Exclusion: - Previous intraocular surgery, Except uncomplicated clear cornea phacoemulsification or argon laser trabeculoplasty - Argon laser trabeculoplasty or phacoemulsification within the last 3 months - Central corneal thickness outside the 500 - 600 (inclusive) micron range as measured by ultrasonic pachymetry - Ocular or periocular inflammation within 3 months prior to study (except blepharitis related or seasonal allergic conjunctivitis) - History of uveitis or previous intraocular inflammation (other than post-operatively) - Hypersensitivity to sulfa, or benzalkonium chloride - History of use of any steroids for over 1 week within 3 months of screening or likely need for any corticosteroids during the study (except inhaled, nasal or topical non-ocular)


NCT ID:

NCT00759941


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Fort Worth, Texas 76134
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.